These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33781693)

  • 1. Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy".
    Satoh H; Miyazaki K; Kagohashi K
    Clin Lung Cancer; 2021 Sep; 22(5):e782. PubMed ID: 33781693
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.
    Hosokawa S; Ichihara E; Bessho A; Harada D; Inoue K; Shibayama T; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 Feb; 51(2):279-286. PubMed ID: 33049757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
    Gambichler T; Doerler M; Scheel CH
    Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
    Kubo T; Watanabe H; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Rai K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1447-1453. PubMed ID: 32869100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:: The Era of Oncodermatopathology.
    Curry JL; Chon SY; Marques-Piubelli ML; Chu EY
    Surg Pathol Clin; 2021 Jun; 14(2):209-224. PubMed ID: 34023101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.
    Duchemann B; Pluvy J; Crestani B; Zalcman G; Nunes H
    Eur J Cancer; 2021 Jul; 151():252-253. PubMed ID: 33958266
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy.
    Johns AC; Sorenson C; Rogers A; Agne JL; D'Souza DM; Das JK; Issa M; Perna G; Williams TM; Meara A; Kitchin T; Haglund KE; Owen DH
    Clin Lung Cancer; 2020 Jul; 21(4):e243-e245. PubMed ID: 32067849
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential New Immune-Checkpoint Inhibitor Partner for Lung Cancer.
    Abbasi J
    JAMA; 2021 Sep; 326(10):901. PubMed ID: 34519817
    [No Abstract]   [Full Text] [Related]  

  • 10. Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer.
    Shannon VR
    Curr Opin Pulm Med; 2020 Jul; 26(4):326-340. PubMed ID: 32452900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
    Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
    Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
    Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
    South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute hyponatremia from immune checkpoint inhibitor therapy for non-small cell lung cancer.
    Desikan SP; Varghese R; Kamoga R; Desikan R
    Postgrad Med J; 2020 Sep; 96(1139):570-571. PubMed ID: 31911447
    [No Abstract]   [Full Text] [Related]  

  • 14. Morphological changes of the thyroid gland as a new radiographic marker for lung cancer treatment efficacy of immune checkpoint inhibitors.
    Itonaga T; Saito K; Ikeda N; Mikami R
    Acta Radiol; 2021 Jan; 62(1):42-50. PubMed ID: 32268773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B; Xiao J; Li J; Liu X; Wang J
    J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non-small cell lung cancer.
    Lin Z; Zhang Y; Zhang L
    Cancer Commun (Lond); 2020 Aug; 40(8):370-373. PubMed ID: 32639662
    [No Abstract]   [Full Text] [Related]  

  • 17. The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis.
    Zheng SY; Cui HJ; Duan H; Peng YM; Li Q; Sun CY; Zhang JY; Shen W; Zhang X; Tan K; Jiang X
    Clin Transl Oncol; 2020 Jul; 22(7):1146-1154. PubMed ID: 31748961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related Encephalitis in Two Patients Treated With Immune Checkpoint Inhibitor.
    Robert L; Langner-Lemercier S; Angibaud A; Sale A; Thepault F; Corre R; Lena H; Ricordel C
    Clin Lung Cancer; 2020 Sep; 21(5):e474-e477. PubMed ID: 32299770
    [No Abstract]   [Full Text] [Related]  

  • 19. Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Popat V; Lu R; Ahmed M; Park JY; Xie Y; Gerber DE
    Oncologist; 2020 Jun; 25(6):515-522. PubMed ID: 32233048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.